Related Experiment Videos
[Extrahepatic cholestasia during therapy with Zolmitriptan (AscoTop)]
1IV. Medizinische Abteilung, Rheumatologie und Klinische Immunologie, Städtisches Klinikum München GmbH, Krankenhaus München-Bogenhausen, Akademisches Lehrkrankenhaus der Technischen Universität München.
Zeitschrift Fur Gastroenterologie
|September 6, 2005
Summary
A patient experienced bile duct issues linked to Zolmitriptan, a migraine drug. Stopping the medication resolved the cholestasis, highlighting the impact of serotonin receptor agonists on the biliary system.
Area of Science:
- Gastroenterology
- Pharmacology
- Hepatology
Background:
- Recurrent abdominal pain, jaundice, and elevated liver function tests prompted investigation in a 62-year-old male.
- Diagnostic imaging revealed dilated extrahepatic bile ducts, with stones and tumors excluded.
Observation:
- Endoscopic retrograde cholangiopancreatography (ERCP) indicated upper gastrointestinal hypermotility.
- Hepatobiliary scintigraphy showed delayed bile excretion, suggesting papillary dysfunction.
Findings:
- The patient's cholestasis syndrome began six months after initiating Zolmitriptan, a 5-HT (1B/1D)-receptor agonist, for migraine treatment.
- Zolmitriptan was discontinued due to potential effects on esophageal motility, similar to Sumatriptan.
- Following Zolmitriptan cessation, liver function tests normalized, and the patient recovered.
Implications:
- This case suggests a potential link between 5-HT (1B/1D)-receptor agonists and biliary dysfunction.
- The findings underscore the role of the serotonergic system in both the central nervous system and the gastrointestinal tract.
- Further research may explore the impact of serotonin agonists on hepatobiliary function.